Drug intelligence / Profile preview

Nova Eyes

Development stage: Unknown
Lead developer: Glamderma
Administration: Intradermal, Subcutaneous

Overview

Nova Eyes is a cosmetic injectable skin booster developed by Glamderma, specifically formulated for the rejuvenation of the periorbital (under-eye) area. The product's active ingredient is polynucleotides (PN) derived from purified salmon milk DNA. As a biologic modality, Nova Eyes works through tissue regeneration mechanisms to repair damage to the dermis, stimulate fibroblast activity, and promote collagen synthesis. It is designed to address aesthetic concerns such as dark circles, fine wrinkles, skin discoloration, and volume loss under the eyes. The product is typically administered via needle mesotherapy, providing hydration and restoring tissue volume to reduce symptoms of fatigue and aging in the periorbital region.

Brand names: Nova Eyes

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Nova Eyes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nova Eyes.

Explore the full profile